Overview

A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic Sclerosis

Status:
Not yet recruiting

Trial end date:
2022-09-27

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether oral temanogrel improves digital blood flow in participants with Raynaud's phenomenon secondary to systemic sclerosis (SSc-RP) as a potential safe and effective treatment for symptoms associated with SSc-RP.

Phase:

Phase 2

Details

Lead Sponsor:

Arena Pharmaceuticals

Treatments:

APD791